All In Biotech

Drug Trial Radar · NCT04643587

Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)

A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of Nebulized CSL787 in Healthy Subjects and Subjects With Non-Cystic Fibrosis Bronchiectasis (NCFB)

Last checked: Nov 19, 2026Latest source record: Dec 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Dec 7, 2020

Primary completion

Mar 12, 2023

Study completion Mar 12, 2023

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
Nov 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a prospective, multicenter, randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and exploratory efficacy of nebulized CSL787 after administrations of single (SAD) ascending doses in healthy subjects and multiple (MAD) ascending doses in subjects with NCFB.

Conditions

  • Noncystic Fibrosis Bronchiectasis (NCFB)

Interventions

  • CSL787Biological

    Human plasma-derived polyvalent immunoglobulin G (IgG) administered via inhalation of an aerosol produced using a nebulizer

  • PlaceboDrug

    Normal saline (0.9% NaCl)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with treatment emergent adverse events (TEAEs) - overall, severity and causalityTime frame: Up to 8 days (healthy volunteers); Up to 21 days (NCFB patients)
  2. Percent of subjects with TEAEs - overall, severity and causalityTime frame: Up to 8 days (healthy volunteers); Up to 21 days (NCFB patients)

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • IKF Pneumologie Institute

    Frankfurt, Germany

  • Medicines Evaluation Unit (MEU)

    Manchester, England, United Kingdom

  • Celerion

    Belfast, Northern Ireland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.